Herrgårdh, Tilda
Simonsson, Christian
Ekstedt, Mattias
Lundberg, Peter
Stenkula, Karin G.
Nyman, Elin
Gennemark, Peter
Cedersund, Gunnar
Funding for this research was provided by:
Vetenskapsrådet (2018-05418, 2018-03319, 2018-03391, 2007-2884, 2014-6157, 2020-04826, 2019-00978, 2018-05418, 2018-03319, 2018-03391)
CENIIT, Center for Industrial Information Technology (15.09)
Stiftelsen för Strategisk Forskning (ITM17-0245)
Knut och Alice Wallenbergs Stiftelse (2020.0182)
H2020 European Institute of Innovation and Technology (777107)
Stiftelsen Forska Utan Djurförsök (F2019-0010)
ELLIIT, Excellence Center at Linköping – Lund in Information Technology (2020-A12)
VINNOVA (2020-04711)
Novo Nordisk (NNF20OC0063659)
Svenska Diabetesstiftelsen
Direktör Albert Påhlssons Stiftelse
Crafoordska Stiftelsen
AstraZeneca Mölndal (employed)
Linköping University
Article History
Received: 7 August 2023
Accepted: 15 November 2023
First Online: 4 December 2023
Declarations
:
: Not applicable.
: Not applicable.
: Cedersund is CEO of the spinoff company SUND sound medical decisions, and Gennemark is employed at AstraZeneca, and both of them own shares in their respective companies.